Holliston biopharma makes CEO permanent
Photo | Courtesy of Biostage, Inc.
David Green, outgoing CEO of Biostage, Inc.
Biostage, Inc. in Holliston has removed the interim designation from David Green’s title and made him biotechnology company’s CEO.
The move went into effect on Wednesday, according to the company’s press release.
Green founded Biostage in 2008 and served as its first CEO. In 2015, he departed as day-to-day leader of the company for about six years. The company was led by CEO James McGorry until he resigned in 2020, as the clinical stage biotechnology company struggled financially.
Green returned to lead the company in November 2021.
Biostage has several patents in the U.S. and is focused on its esophageal implant product, which is used to treat esophageal cancer. Throughout its clinical research, the company has received significant funding from Chinese investors, as the rate of throat cancer is high in China.
“I am an investor in Biostage and most of my compensation will be in the form of stock options. Hence my interests are aligned with those of our shareholders in making Biostage successful," Green said in a press release.
WBJ Web Partners
Most Recent
Most Recent
0 Comments